Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer

Summary

The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.

Eligibility

Inclusion Criteria:

* Age 18 or older
* Pathological diagnosis of suspected epithelial ovarian cancer; of note, patients with suspected epithelial ovarian cancer who are pending a pathological diagnosis/biopsy may be enrolled onto the study ahead of their biopsy. If the biopsy result is later inconsistent with epithelial ovarian cancer, they will be removed from the study and replaced
* Planned to received neoadjuvant chemotherapy with carboplatin and paclitaxel; alternatives to these agents including abraxane, docetaxel, cisplatin may be used if patients have a chemotherapy reaction or otherwise cannot receive carboplatin and paclitaxel per usual standard of care
* Patients may be receiving bevacizumab and may receive PARP inhibitors as a maintenance treatment; those receiving any other targeted therapy will be excluded

Exclusion Criteria:

* History of diagnosed cognitive impairment, including dementia
* History of traumatic brain injury
* English is not their primary language
* Known hearing or visual impairment not corrected with hearing devices and glasses/contacts
* Upper extremity motor impairment that would impact ability to perform the Trail Making Test
* Baseline Mini Mental State Exam (MMSE) score less than 18

Conditions3

Locations1 site

Browse More Trials